ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs.


Updates from The Motley Fool

Latest updates on ImmunoGen from Fool.com.


Stock Performance

IMGN vs. S&P 500 | 2 Year Performance
View Interactive IMGN Charts
Sponsored by

Key Data Points

Primary metrics and data points about ImmunoGen.
Current Price: $2.90
Prev Close: $2.92
Open: $2.94
Bid: $2.86
Ask: $2.94
Day's Range: $2.81 - $2.98
52wk Range: $2.53 - $16.59
Volume: 739,377
Avg Vol 1,254,004
Market Cap: $252.26M
P/E (ttm): -1.75
EPS (ttm): -$1.67
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about ImmunoGen.
CAPS Rating 4 out of 5
 
322 Outperform
21 Underperform
CAPS All Stars
 
58 Outperform
2 Underperform

How do you think ImmunoGen will perform against the market?



You pick for ImmunoGen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Dan Junius, CEO

68% Approve

Based on 17 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for ImmunoGen.

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers